bioMérieux is a French IVD company specializing in microbiology, molecular diagnostics, and applied microbiology for food and pharmaceutical testing, with revenues of approximately $4.5 billion in 2025. The company is the global leader in automated blood culture (BacT/ALERT), clinical microbiology (VITEK), and molecular syndromic testing (BIOFIRE FilmArray). The BIOFIRE FilmArray syndromic panels — covering respiratory, gastrointestinal, blood culture identification, meningitis/encephalitis, and pneumonia — are the market-leading multiplex molecular syndromic testing platforms globally. bioMérieux's acquisition of SpinChip in 2024 secured a beachhead in microfluidics-based near-patient testing. The applied microbiology business serves pharmaceutical quality control and food safety testing markets.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — BIOFIRE Expansion, Microbiology Leadership, and Applied Microbiology Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — BIOFIRE FilmArray, VITEK, BacT/ALERT, and SpinChip
• Latest Products and Services — Platform Launches, Menu Expansions, and Innovation Pipeline
• M&A — SpinChip Acquisition, Joint Ventures, and Partnerships 2023-2025
• Marketing Tactics — Syndromic Panel Strategy, Applied Microbiology Positioning, and Channel
• Organization and Management — Leadership, Structure, and Workforce
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. bioMérieux — Key Financial Metrics Summary 2023-2025
Table 2. bioMérieux — Revenue by Segment 2023-2025
Table 3. bioMérieux — Revenue by Geography 2023-2025
Table 4. bioMérieux — R&D Investment 2023-2025
Table 5. bioMérieux — SWOT Analysis
Table 6. bioMérieux — Core Technology Capabilities and Key Platforms
Table 7. bioMérieux — Key Analyzers and Reagent Portfolio
Table 8. bioMérieux — M&A Activity Summary 2023-2025
Table 9. bioMérieux — Key Management and Leadership
Table 10. bioMérieux — Strategic Priorities 2025-2030
